ORIGINAL ARTICLE

Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas

A Mohyuddin¹, W J Neary², A Wallace¹, C L Wu¹, S Purcell¹, H Reid³, R T Ramsden⁴, A Read¹, G Black¹, D G R Evans¹

¹ University Department of Medical Genetics and Regional Genetic Services, St Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK
² Warrington Community Health Care (NHS) Trust, Child and Family Services Unit, Guardian House, Guardian Street, Warrington WA5 ITP, UK
³ Department of Pathology, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
⁴ Department of Otolaryngology, Head and Neck Surgery, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK

Correspondence to:
Correspondence to:
Mr A Mohyuddin, FRCS, University Department of Medical Genetics and Regional Genetic Services, St Mary's Hospital, Hathersage Road, Manchester M13 OJH, UK;
atai_1999{at}yahoo.com

Neurofibromatosis type 2 (NF2) must be suspected in patients presenting with a unilateral vestibular schwannoma at a young age who are therefore at theoretical risk of developing bilateral disease. We identified 45 patients aged 30 years or less at the onset of symptoms of a unilateral vestibular schwannoma. Molecular genetic analysis of the NF2 gene was completed on peripheral blood samples in all 45 and on 28 tumour samples. No pathogenic NF2 mutations were identified in any of the blood samples. NF2 point mutations were identified in 21/28 (75%) tumour samples and loss of heterozygosity (LOH) in 21/28 (75%) tumour samples. Both mutational hits were identified in 18/28 (65%) tumour samples. In one multilobular tumour, one (presumably first hit) mutation was confirmed which was common to different foci of the tumour, while the second mutational event differed between foci. The molecular findings in this patient were consistent with somatic mosaicism for NF2 and the clinical diagnosis was confirmed with the presence of two meningiomas on a follow up MRI scan. A further patient developed a contralateral vestibular schwannoma on a follow up MRI scan in whom neither of the truncating mutations in the vestibular schwannoma were present in blood.

It is important when counselling patients with unilateral vestibular schwannomas to identify (1) those at risk of bilateral disease, (2) those at risk of developing other tumours, and (3) other family members at risk of developing NF2. Comparing tumour and blood DNA cannot exclude mosaicism in the index case and cannot, therefore, be used to predict those at risk of developing further tumours. However, identification of both mutations or one mutation plus LOH in the tumour and exclusion of those mutations in the blood samples of the sibs or offspring of the affected case may be sufficient to render further screening unnecessary in these relatives.

Keywords: neurofibromatosis type 2; vestibular schwannoma; mutation; somatic mosaicism

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hadfield, K D, Newman, W G, Bowers, N L, Wallace, A, Bolger, C, Colley, A, McCann, E, Trump, D, Prescott, T, Evans, D G R (2008). Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J. Med. Genet. 45: 332-339 [Abstract] [Full Text]  
• Evans, D G. R, Ramsden, R T, Shenton, A, Gokhale, C, Bowers, N L, Huson, S M, Pichert, G, Wallace, A (2007). Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J. Med. Genet. 44: 424-428 [Abstract] [Full Text]  
• Evans, D G R, Birch, J M, Ramsden, R T, Sharif, S, Baser, M E (2006). Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J. Med. Genet. 43: 289-294 [Abstract] [Full Text]  
• Diebold, R., Bartelt-Kirbach, B., Evans, D. G., Kaufmann, D., Hanemann, C. O. (2005). Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction. J. Mol. Diagn. 7: 97-104 [Abstract] [Full Text]  
• Baser, M. E., Friedman, J. M., Wallace, A. J., Ramsden, R. T., Joe, H., Evans, D. G.R. (2002). Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759-1765 [Abstract] [Full Text]  
• Kressel, M., Schmucker, B. (2002). Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum Mol Genet 11: 2269-2278 [Abstract] [Full Text]